Alnylam Pharmaceuticals, Inc. (ALNY) Upgraded to “Strong-Buy” at BidaskClub
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.
ALNY has been the topic of a number of other reports. ValuEngine raised shares of Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Piper Jaffray Companies set a $116.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 24th. Credit Suisse Group reissued a “hold” rating and issued a $50.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 9th. Needham & Company LLC boosted their price target on shares of Alnylam Pharmaceuticals from $68.00 to $98.00 and gave the stock a “buy” rating in a report on Tuesday, June 27th. Finally, Morgan Stanley boosted their price target on shares of Alnylam Pharmaceuticals from $39.00 to $42.00 and gave the stock an “equal weight” rating in a report on Monday, May 8th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $79.79.
Shares of Alnylam Pharmaceuticals (ALNY) opened at 82.44 on Friday. The firm’s market cap is $7.11 billion. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $86.92. The firm has a 50-day moving average of $80.45 and a 200-day moving average of $59.96.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. The firm had revenue of $19 million during the quarter, compared to the consensus estimate of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The business’s revenue was up 160.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.21) EPS. On average, analysts expect that Alnylam Pharmaceuticals will post ($5.19) EPS for the current year.
In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 11,000 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total transaction of $825,000.00. Following the transaction, the executive vice president now directly owns 21,297 shares in the company, valued at $1,597,275. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Michael Mason sold 9,375 shares of the stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the transaction, the vice president now owns 5,625 shares in the company, valued at $393,750. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,125 shares of company stock worth $4,325,000. 4.30% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. First Manhattan Co. acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $135,000. CIBC Asset Management Inc acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $221,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $148,000. Capstone Asset Management Co. acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $232,000. Finally, Hemenway Trust Co LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $235,000. Institutional investors and hedge funds own 88.96% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.